Sign In  |  Register  |  About Menlo Park  |  Contact Us

Menlo Park, CA
September 01, 2020 1:28pm
7-Day Forecast | Traffic

  • Search Hotels in Menlo Park

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by NGM Biopharmaceuticals, Inc.

NGM Bio Announces $122 Million Series A Financing to Initiate Registrational Trial in Primary Sclerosing Cholangitis and Fund Phase 2 Trial in Hyperemesis Gravidarum
From NGM Biopharmaceuticals, Inc.
Via GlobeNewswire
NGM Bio Announces Closing of Tender Offer
From NGM Biopharmaceuticals, Inc.
Via GlobeNewswire
Tickers NGM
NGM Bio to Present Two Posters Highlighting Clinical Data from the Ongoing Phase 1/2 Clinical Trial of NGM707, a Dual ILT2/ILT4 Antagonist Antibody Product Candidate, at AACR 2024 Annual Meeting
From NGM Biopharmaceuticals, Inc.
Via GlobeNewswire
Tickers NGM
NGM Bio Provides Recent Business Highlights and Reports Fourth Quarter and Full Year 2023 Financial Results
From NGM Biopharmaceuticals, Inc.
Via GlobeNewswire
Tickers NGM
NGM Bio Has Entered into a Definitive Agreement and Plan of Merger with Certain Affiliates of The Column Group, LP
From NGM Biopharmaceuticals, Inc.
Via GlobeNewswire
Tickers NGM
NGM Bio to Participate in the Cowen 44th Annual Health Care Conference
From NGM Biopharmaceuticals, Inc.
Via GlobeNewswire
Tickers NGM
NGM Bio to Participate in the B. Riley Securities 4th Annual Oncology Conference
From NGM Biopharmaceuticals, Inc.
Via GlobeNewswire
Tickers NGM
NGM Bio Announces New Clinical Data from Ongoing Trial of NGM707 in Advanced Solid Tumors and Outlines Evolved Strategy for Aldafermin and NGM120 to Focus on Rare Conditions with Significant Unmet Need
From NGM Biopharmaceuticals, Inc.
Via GlobeNewswire
Tickers NGM
NGM Bio Presents Positive Phase 2b Results from the ALPINE 4 Trial of Aldafermin in Patients with Compensated Cirrhosis (F4) Due to NASH at AASLD The Liver Meeting®
From NGM Biopharmaceuticals, Inc.
Via GlobeNewswire
Tickers NGM
NGM Bio to Participate in Upcoming Investor Conferences
From NGM Biopharmaceuticals, Inc.
Via GlobeNewswire
Tickers NGM
NGM Bio Reports Third Quarter 2023 Financial Results and Provides Business Highlights
From NGM Biopharmaceuticals, Inc.
Via GlobeNewswire
Tickers NGM
NGM Bio Announces Oral Plenary Presentation of Data from Phase 2b ALPINE 4 Trial of Aldafermin in Compensated Cirrhosis (F4) Due to NASH at Upcoming AASLD The Liver Meeting®
From NGM Biopharmaceuticals, Inc.
Via GlobeNewswire
Tickers NGM
NGM Bio Reports Second Quarter 2023 Financial Results and Provides Business Highlights
From NGM Biopharmaceuticals, Inc.
Via GlobeNewswire
Tickers NGM
NGM Bio to Participate in Upcoming Investor Conferences
From NGM Biopharmaceuticals, Inc.
Via GlobeNewswire
Tickers NGM
NGM Bio Announces Presentation of Data from Phase 2 Investigator-Sponsored Trial of Aldafermin for the Treatment of Patients with Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) and Bile Acid Malabsorption (BAM) at Digestive Disease Week 2023
From NGM Biopharmaceuticals, Inc.
Via GlobeNewswire
Tickers NGM
NGM Bio Reports First Quarter 2023 Financial Results and Provides Business Highlights, Including Topline ALPINE 4 Data
From NGM Biopharmaceuticals, Inc.
Via GlobeNewswire
Tickers NGM
NGM Bio to Participate in the Cowen 43rd Annual Health Care Conference
From NGM Biopharmaceuticals, Inc.
Via GlobeNewswire
Tickers NGM
NGM Bio Provides Business Highlights and Reports Fourth Quarter and Full Year 2022 Financial Results
From NGM Biopharmaceuticals, Inc.
Via GlobeNewswire
Tickers NGM
NGM Bio to Participate in the B. Riley Securities 3rd Annual Oncology Conference
From NGM Biopharmaceuticals, Inc.
Via GlobeNewswire
Tickers NGM
NGM Bio Outlines Corporate Strategy and Provides Guidance on Key Priorities
From NGM Biopharmaceuticals, Inc.
Via GlobeNewswire
Tickers NGM
NGM Bio Gives Presentation Featuring Preclinical Characterization of NGM936 at 2022 ASH Annual Meeting
From NGM Biopharmaceuticals, Inc.
Via GlobeNewswire
Tickers NGM
NGM Bio Presents Preliminary Data from Phase 1 Monotherapy Dose Escalation Trial of NGM707 in Patients with Advanced or Metastatic Solid Tumors at 2022 ESMO-IO Annual Meeting
From NGM Biopharmaceuticals, Inc.
Via GlobeNewswire
Tickers NGM
NGM Bio Announces Poster Presentation Featuring Initial Findings from Ph1a Trial of NGM707 in Patients with Advanced Solid Tumors at Upcoming 2022 ESMO-IO Annual Meeting
From NGM Biopharmaceuticals, Inc.
Via GlobeNewswire
Tickers NGM
NGM Bio Announces Poster Presentation Featuring Preclinical Characterization of NGM936 at Upcoming 2022 ASH Annual Meeting
From NGM Biopharmaceuticals, Inc.
Via GlobeNewswire
Tickers NGM
NGM Bio Provides Business Highlights and Reports Third Quarter 2022 Financial Results
From NGM Biopharmaceuticals, Inc.
Via GlobeNewswire
Tickers NGM
NGM Bio Announces Topline Results from the CATALINA Phase 2 Trial of NGM621 in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration
From NGM Biopharmaceuticals, Inc.
Via GlobeNewswire
Tickers NGM
NGM Bio Announces Presentation of Post-Hoc Analyses from CATALINA Phase 2 Trial of NGM621 in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) at The Retina Society Annual Scientific Meeting
From NGM Biopharmaceuticals, Inc.
Via GlobeNewswire
Tickers NGM
NGM Bio to Host Conference Call to Discuss Topline Results from the CATALINA Phase 2 Trial of NGM621 in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration
From NGM Biopharmaceuticals, Inc.
Via GlobeNewswire
Tickers NGM
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MenloPark.com & California Media Partners, LLC. All rights reserved.